Glecaprevir
A NS3/4A protease inhibitor used as part of a combination antiviral regimen to treat chronic hepatitis C infection across all major genotypes. It works by blocking a viral enzyme essential for processing the hepatitis C polyprotein into functional components required for viral replication. When combined with pibrentasvir, it offers a highly effective pan-genotypic cure with a short treatment duration.
Molecular Weight
838.9000 g/mol
LogP
4.60
TPSA
204.00 Ų
Lipinski RO5
Fail
Therapeutic Areas
Mechanism of Action
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O
InChI
InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
Molecular Formula
C38H46F4N6O9S
HBD / HBA
3 / 15
Rotatable Bonds
7
Heavy Atoms
58
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A NS3/4A protease inhibitor used as part of a combination antiviral regimen to treat chronic hepatitis C infection across all major genotypes. It works by blocking a viral enzyme essential for processing the hepatitis C polyprotein into functional components required for viral replication. When combined with pibrentasvir, it offers a highly effective pan-genotypic cure with a short treatment duration.
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
Yes, Glecaprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545363. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 66828839. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glecaprevir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glecaprevir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glecaprevir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glecaprevir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glecaprevir"></drugfyi-drug>